Reach Us +1-504-608-2390
Editor - Tsutomu Yasukawa | Nagoya University | 277
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Tsutomu Yasukawa

Tsutomu Yasukawa
Tsutomu Yasukawa
Associate Professor
Department of Ophthalmology and Visual Science
Nagoya University
Tel: 81-52-8538251
Fax: 81-52-8419490
Nagoya University


Tsutomu Yasukawa is Associate Professor of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences in Japan. He graduated from Kyoto University Graduate School of Medicine, Kyoto, Japan in 1993 and received a PhD in Medicine in 2000. He was a research fellow in Leipzig University, Leipzig, Germany in 2000–2002 as a scholar of Alexander Humboldt Foundation. He is serving as an editorial board member of 4 journals.

Research Interest

He is an expert in drug delivery systems to the posterior segments of the eye. His group has introduced a variety of intraocular drug delivery systems (1) controlled release systems using biodegradable or non degradable intraocular implants, microspheres, or gelatin hydrogel and (2) drug targeting using drug conjugated with water soluble polymers or antibodies. Some of these strategies are currently under clinical trial in the treatment of uveitis, macular edema, or age related macular degeneration (AMD)